

Melanoma Treatments

Reference Number: RDF1913-23

Date of Response: 16/10/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I am trying to understand how Pembrolizumab is used in the treatment of Melanoma.

Could you please answer the following:

- 1. How many patients have you treated with Pembrolizumab in the three months from May 2023 to July 2023 for:*

Answer: Please see table below.

Staging	Patients
<i>Melanoma - any stage</i>	53
<i>Stage IIb/IIc Melanoma</i>	6
<i>Stage III Melanoma</i>	29
<i>Metastatic Melanoma</i>	17

- 2. How many Stage IIb/IIc melanoma patients were on a "Watch and Wait" strategy in the three months from May 2023 to July 2023? These would be patients where a decision has been made to wait before commencing any treatment.*

Answer: ≤5.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.